Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (A10AC) — coverage varies; not interchangeable

  • Insulin isophane human biosynthetic (Novolin ge NPH): general benefit

Humulin NPH · DIN 00587737 · 1000U/10mL · injection suspension-10mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Humulin NPH · DIN 00587737 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 1997-12-11 · brand HUMULIN N · ATC A10AC01 INSULIN (HUMAN) · form Suspension · route Subcutaneous · ingredients INSULIN NPH HUMAN DNA ORIGIN 100 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Humulin NPH: Formulary list price $29.9800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $29.9800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5326 · Verify on the e-Formulary ↗ (DIN 00587737)

Source record
DIN 00587737: Humulin NPH Raw flags: insOH=Y, sec3=Y Item: 682012007; group id 777; item number 1893; lccId None; manufacturer id LIL Source form: Inj Susp-10mL Pk; strength: 1000U/10mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $29.9800; ministry $29.9800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00587737 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5326
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00587737
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Humulin N · PIN 09853804 · 100U/mL · injectable suspension, 5 x 3 mL

General benefitOntario PIN; no Health Canada record under this code
Write on scriptno code needed

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Humulin N · DIN 09853804 Manufacturer: Eli Lilly Canada Inc.; listing date 1998-12-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Humulin N: Formulary list price $61.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $61.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853804)

Source record
DIN 09853804: Humulin N Raw flags: insOH=Y, sec3=Y Item: 682012018; group id 777; item number 1894; lccId None; manufacturer id LIL Source form: Inj Susp-5x3mL Pk; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $61.7600; ministry $61.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09853804 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853804
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:12 Insulins (Intermediate Acting)) and how they are covered

Matched class: 68:20:12 Insulins (Intermediate Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC 68:20:12 Insulins (Intermediate Acting)

INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:12
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: insulin requiring diabetic patients
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70% INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70% · General benefit INDICATIONS AND CLINICAL USE HUMULIN (insulin, human biosynthetic) is indicated for the treatment of insulin requiring diabetic patients. PM: https://pdf.hres.ca/dpd_pm/00060544.PDF; date March 26, 2021; DIN 00795879; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HUMULIN (insulin, human biosynthetic) is indicated for the treatment of insulin requiring diabetic patients. HUMULIN-R only should be used for the treatment of emergencies such as diabetic coma and pre-coma and in diabetics undergoing surgery, but not HUMULIN-N, or HUMULIN MIXTURES. In switching patients from animal source insulins to HUMULIN, it is possible that the patients will require a change in dosage; the adjustment may be made with the first dose or over a period of several weeks. Any change of insulin should be made cautiously and only under medical supervision. Changes in refinement, purity, strength, brand, type and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage. HUMULIN Product Monograph Page 3 of 54 https://pdf.hres.ca/dpd_pm/00060544.PDF PM date: March 26, 2021 Source product: HUMULIN N; DIN 00587737; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Humulin NPH · DIN 00587737 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00587737

Check this DIN again